

Company Highlights

- Offering a generic pharmaceutical product portfolio of over 210 NDC's spanning 65 product families
- Dosage forms available include oral solids, liquids, injectables, and topicals
- Wockhardt USA LLC represents 20% of Wockhardt's global business
- Sales growth of 140% for 2008 versus 2007
- Ten products launched in 2007; twenty-three launched in 2008
- Azithromycin Tablets, Phenytoin Sodium ER Caps, Ropinirole, Midazolam inj, Granisetron inj, Risperidone launched in 2008. Divalproex ER Tabs and Sumatriptan pens and vials will launch in 2009
- 17 product launches planned for 2009
- Over 50 ANDA's pending approval from the FDA
- Vertical integration of products via our manufacturing plants in the US, Europe and India

